Skip to content

CEO video statement. Q1 2025.

A Transformative Quater for Gubra 

Today, we share our Q1 2025 results – a quarter marked by a transformative milestone: 

 We’ve entered into an out-licensing agreement with AbbVie for our internally developed anti-obesity asset GUBamy. This landmark deal represents a potential value of USD 2.2 billion in upfront and milestone payments plus royalties on net sales. 

 We invite you to read the full press release or watch this video where our CEO, Henrik Blou, shares the highlights and progress of this remarkable quarter. 

Share this page

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

[email protected]
+45 3152 ­2650

Back To Top